Clinical experience with NuvaRing® in daily practice in Switzerland: Cycle control and acceptability among women of all reproductive ages

European Journal of Contraception and Reproductive Health Care

Volumn 12, Issue 3, 2007, Pages 240-247

  Merki Feld, Gabriele S ^a   Hund, Martin ^b,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Organon AG   (Switzerland)

^c NONE   (Switzerland)

Author keywords

Acceptability; Cycle control; Daily practice; NuvaRing ; Satisfaction; Young women

Indexed keywords

ETHINYLESTRADIOL PLUS ETONOGESTREL;

ACNE; ADOLESCENT; ADULT; ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSMENORRHEA; FEMALE; HORMONAL CONTRACEPTION; HUMAN; LEUKORRHEA; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MIGRAINE; MOOD CHANGE; MOOD DISORDER; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; REPRODUCTION; SIDE EFFECT; SWITZERLAND; TREATMENT DURATION; VAGINAL DISCOMFORT; VAGINAL DRYNESS;

ADOLESCENT; ADULT; AGE FACTORS; BLOOD PRESSURE; BODY WEIGHT; CONTRACEPTIVE DEVICES, FEMALE; DESOGESTREL; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PREGNANCY; PROSPECTIVE STUDIES; QUESTIONNAIRES; SWITZERLAND;

EID: 34548315897     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180701440180     Document Type: Article

References (16)

1. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39:233-42.
2. van den Heuvel M, van Bragt A, Alnabawy A, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168-74.
3. Roumen FJ, Apter D, Mulders TM, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001;16:469-75.
4. Oddsson K, Leifels-Fischer B, de Melo NR, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: A 1-year randomized trial. Contraception 2005;72:176-82.
5. Ahrendt H-J, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74:451-7.
6. Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ ethinyl estradiol. Am J Obstet Gynecol 2002;186:389-95.
7. Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 (micro)g ethinylestradiol and 150 (micro)g levonorgestrel: a randomized trial. Hum Reprod 2005;20:557-62.
8. Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 (micro)g ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21:2304-11.
9. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1988;179:577-82.
10. Gallo MF, Nanda K, Grimes DA, et al. 20 mcg versus >20 mcg Estrogen combined oral contraceptives for contraception. The Cochrane Database of Systematic Reviews 2006, Issue 1.
11. Novák A, de la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing: An international study of user acceptability. Contraception 2003;67:187-94.
12. Rosenberg MJ, Burnhill MS, Waugh MS, et al. Compliance and oral contraceptives: A review. Contraception 1995;52:137-41.
13. Benedetto C, Lounsbach G. European women's survey on oral contraceptive use. Eur J Contracept Reprod Health Care 2004;9(Suppl 1):77.
14. Nap M, Apter D, Tuomivaara L. Acceptability of NuvaRing in young women. Eur J Contracept Reprod Health Care 2004;9(Suppl 1):176.
15. Roumen FJ, op ten Berg MM, Hoomans EH. The combined contraceptive vaginal ring (NuvaRing): First experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care 2006; 11:14-22.
16. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995;51:283-8.